Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

por Verma, Subodh, Fainberg, Udi, Husain, Mansoor, Rasmussen, Søren, Rydén, Lars, Ripa, Maria Sejersten, Buse, John B.
Publicado 2021

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the...

por Leiter, Lawrence A., Bain, Stephen C., Bhatt, Deepak L., Buse, John B., Mazer, C. David, Pratley, Richard E., Rasmussen, Søren, Ripa, Maria Sejersten, Vrazic, Hrvoje, Verma, Subodh
Publicado 2020

Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study

por Jensen, Jakob Solgaard, Weeke, Peter Ejvin, Bang, Lia Evi, Høfsten, Dan Eik, Ripa, Maria Sejersten, Schjerning, Anne-Marie, Theilade, Juliane Elizabeth, Køber, Lars Valeur, Gislason, Gunnar Hilmar, Pallisgaard, Jannik
Publicado 2019